Bristol Myers Squibb Company $BMY Shares Purchased by Profund Advisors LLC

Profund Advisors LLC grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 68.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,019 shares of the biopharmaceutical company’s stock after buying an additional 18,717 shares during the quarter. Profund Advisors LLC’s holdings in Bristol Myers Squibb were worth $2,872,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp raised its position in Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the second quarter worth about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Bristol Myers Squibb by 0.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after purchasing an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after purchasing an additional 520,330 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BMY shares. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 19th. Wells Fargo & Company lowered their price target on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 13th. Morgan Stanley lowered their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a research report on Friday. TD Cowen assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating for the company. Finally, Truist Financial set a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $65.46.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $62.46 on Monday. The stock has a market capitalization of $127.67 billion, a P/E ratio of 13.85, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 1 year low of $45.20 and a 1 year high of $68.64. The firm has a 50 day moving average of $62.80 and a 200-day moving average of $59.94.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period last year, the firm posted $1.63 EPS. The business’s revenue was up 6.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.40 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.